Amgen (FRA:AMG) Interest Expense: €-2,311 Mil (TTM As of Mar. 2026)


FRA:AMG Amgen Inc FRA:AMG
88 GF Score
Price €326.65
GF Value €308.79
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Amgen Interest Expense?

Amgen FRA:AMG +2.08% 88 Interest Expense is €-2,311 Mil as of Mar. 2026. GuruFocus rates FRA:AMG with a GF Score™ of 88/100 and a GF Value™ of €308.79 (Fairly Valued). The stock has 9 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amgen's interest expense for the three months ended in Mar. 2026 was € -568 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-2,311 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amgen's Operating Income for the three months ended in Mar. 2026 was € 2,306 Mil. Amgen's Interest Expense for the three months ended in Mar. 2026 was € -568 Mil. Amgen's Interest Coverage for the quarter that ended in Mar. 2026 was 4.06. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amgen  (FRA:AMG) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amgen's Interest Expense for the three months ended in Mar. 2026 was €-568 Mil. Its Operating Income for the three months ended in Mar. 2026 was €2,306 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €44,881 Mil.

Amgen's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*2306.09/-568.305
=4.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Amgen Interest Expense Historical Data

* Premium members only.

The historical data trend for Amgen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Interest Expense Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,059.35 -1,327.26 -2,636.38 -3,013.03 -2,352.77

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -668.78 -601.70 -583.62 -557.66 -568.31
FRA:AMG
88GF Score
Amgen Inc FRA:AMG
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,311 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-2,311 Mil mean?
Amgen (FRA:AMG) has a Interest Expense of €-2,311 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Amgen and its competitors.
Is Amgen's Interest Expense too high?
Amgen's current Interest Expense is €-2,311 Mil. Overall, Amgen has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Interest Expense compare to GILD and PFE?
Amgen's Interest Expense of €-2,311 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Amgen and its competitors. Amgen's current Interest Expense is €-2,311 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.79, compared to a current price of €326.65 — trading 5.8% above its estimated fair value. The current Interest Expense is €-2,311 Mil. Amgen's overall GF Score™ is 88/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Interest Expense is €-2,311 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €326.65 is trading 5.8% above its estimated GF Value™ of €308.79. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Interest Expense: €-2,311 Mil
  • GF Value™: €308.79 vs. price of €326.65 (5.8% above fair value)
  • GF Score™: 88/100 with 9 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
88GF Score

Get the complete analysis for FRA:AMG

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€326.65
Price
€308.79
GF Value